Lupin launches generic medication, to be manufactured in Nagpur, in US


Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market

Topics


Lupin | Pharmaceutical | US FDA

Lupin

Drug maker Lupin on Tuesday said it has launched Sevelamer Hydrochloride tablets (800 mg), used to treat hyperphosphatemia in patients with chronic kidney disease, in the US market.

The company has launched the product after having received approval from the US Food and Drug Administration (USFDA).

The medication will be manufactured at the company’s manufacturing facility in Nagpur, Lupin said in a statement.

Hyperphosphatemia refers to abnormally high serum phosphate levels.

The company’s product is a generic equivalent of Genzyme Corporation’s Renagel tablets.

As per IQVIA MAT December 2021 data, Sevelamer Hydrochloride tablets (800 mg) had an estimated annual sales of USD 75 million in the US.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.


We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, March 01 2022. 17:39 IST